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Absence of hemolytic disease of fetus and 
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Anti-Ku seen in K0 (Kell-null) individuals has previously been 
shown to cause severe hemolytic transfusion reactions. Mater-
nal anti-Ku can cause none or moderate to severe hemolytic 
disease of the fetus and newborn (HDFN). In two of four pre-
viously described HDFN cases, intrauterine transfusions were 
required because of severe anemia. We report a case in which 
maternal anti-Ku did not cause HDFN. Standard serologic 
methods were used for RBC antibody screening and identifi-
cation, adsorption and elution of RBC antibodies, and antigen 
typing. A gravida 3, para 3 (G3P3) woman was first evaluated 
in 2006 and was found to have an IgG RBC antibody that re-
acted against all panel RBCs in the anti-human globulin phase. 
A panel of RBCs treated with DTT did not react with the an-
tibody.  The antibody failed to react with one example of K0 
RBCs. The patient’s RBCs typed negative for the following Kell 
blood group antigens: KEL1, KEL2, KEL3, KEL4, KEL6, KEL7, 
KEL11, KEL13, and KEL18. These results established the pres-
ence of anti-Ku in maternal serum. The newborn was group A, 
D+ and required phototherapy for hyperbilirubinemia, but did 
not require transfusion. The woman was seen again in January 
2010 during the third trimester (G4P3). At this time, anti-Ku 
titer was 256. She delivered a healthy group O, D+ baby boy 
at 37 weeks’ gestation. Cord RBCs were 4+ for IgG by DAT. 
An eluate reacted with all RBCs tested, but did not react when 
tested against a panel of DTT-treated RBCs. K0 phenotype is 
rare to begin with, and the maternal anti-Ku formation may re-
quire more than one pregnancy. Therefore, cases that can be 
evaluated for anti-Ku–related HDFN are rare. Our case con-
tributes to serologic and clinical aspects of such rare cases. 
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The Kell blood group system is polymorphic and is known to contain both low- and high-prevalence antigens. KEL1 (synonyms K, Kell), KEL3 (syn-
onym Kpa), and KEL6 (synonym Jsa) are examples of low-
prevalence antigens, and KEL2 (synonyms k, Cellano), 
KEL4 (synonym Kpb), and KEL7 (synonym Jsb) are high- 
prevalence antigens. An antithetical relationship between 
some of the low- and high-prevalence antigens, for example, 
KEL3 and KEL4, has been described. Kell system antibodies 
directed toward the low- and high-prevalence antigens are 
known to be clinically significant. Antibody against a high- 
prevalence antigen KEL5 (synonym Ku) is made by indi-
viduals with K0 RBCs that lack all Kell antigens, i.e., are K0 
(Kell-null). Other examples of high-prevalence antigens 
include KEL11, KEL12, KEL13, KEL14, KEL16, KEL18, 
KEL19, KEL20, and KEL22. Kx antigen is phenotypically 
related to the Kell blood group, but is coded by a gene lo-
cated on the X chromosome. The Kell blood group system 
was reviewed by Westhoff and Reid.1
 For routine blood banking, commercial antibodies 
directed toward KEL1, KEL2, and KEL3 are available for 
patient and donor typing. Commercial panel RBCs charac-
terized for these antigens and others, such as KEL4, KEL6, 
and KEL7, are available for antibody detection and identi-
fication. Kell blood group antigens are inactivated by treat-
ment of RBCs with 2-aminoethylisothiouronium (AET) or 
DTT. This characteristic is valuable in the identification of 
Kell antibodies.
 Kell blood group antibodies are known to cause anemia 
of the fetus and newborn (AFN). In one study of 311 KEL1-
alloimmunized pregnant women who had 459 pregnancies, 
376 infants were not affected at birth but 20 were affected.2 
The 376 unaffected infants were KEL1–except for rare cases 
for which paternal or cord blood sample was not available 
for investigation. Of the affected infants, 12 did not require 
treatment although their RBCs were positive by the DAT; 
4 needed exchange transfusion, phototherapy or both; 1 
had moderately severe disease requiring multiple exchange 
transfusions; and 3 had very severe disease requiring fetal 
transfusions, or were hydropic or stillborn. In this report, 4 
infants with severe fatal AFN were observed in the remote 
past (1948–1954).2 These data show that most maternal 
anti-KEL1 do not cause AFN.
 As noted previously, some maternal anti-KEL1 can 
cause AFN. Most frequently these antibodies cause fetal 
anemia through suppression of fetal erythropoiesis. Hemo-
lysis and erythropoiesis suppression together can cause se-
vere anemia in the fetus and the newborn. Kell antigens are 
present on erythroid, myeloid, and megakaryocytic precur-
sors. As a result, maternal anti-KEL1 can cause severe fetal 
anemia and also severe thrombocytopenia.
 In the general population, absence of phenotypic ex-
pression of Kell antigens is rare, and this phenotype is 
referred to as K0. Individuals with the K0 phenotype can 
form antibodies that react with RBCs from all individuals 
except those who are K0. Such antibodies are referred to as 
anti-Ku (KEL5). Anti-Ku can cause hemolysis if patients 
are transfused with incompatible RBCs.3 In fact, a fatal he-
molytic transfusion reaction after transfusion of 34 units of 
Original Report
IMMUNOHEMATOLOGY, Volume 26, Number 3, 2010120
incompatible RBCs has been described.4 In addition to the 
hemolytic transfusion reaction, maternal anti-Ku has been 
described as the cause of AFN in four patients.5–8 Addition-
ally, lack of AFN from such antibodies has also been ob-
served previously (personal communication from Marion 
Reid, April 4, 2010). The first case of AFN from anti-Ku was 
reported by Corcoran et al. in 1961.9 The details regarding 
the degree or the severity of hemolysis and its effect on the 
fetus or newborn were not included in the report. Absence 
of AFN from maternal anti-Ku has been noted previously.10 
Because the K0 phenotype is rare and women with this phe-
notype must be alloimmunized with perhaps more than 
one pregnancy, finding such rare cases to study is difficult. 
Therefore, in this report we describe our case in which ma-
ternal anti-Ku did not cause AFN.
Material and Methods
 Testing for ABO, Rh, and Kell system antigens was per-
formed with commercially available reagents (ABO, Rh, 
KEL1, KEL2, and KEL3 typing sera were from Immucor-
Gamma Inc., Norcross, GA) by the tube method. In-house, 
single-donor source anti-KEL4, anti-KEL6, anti-KEL7, 
anti-KEL11, anti-KEL13, and anti-KEL18 were used to type 
for respective Kell antigens. Antibody screening and iden-
tification methods used tube testing with commer-
cially available reagent RBCs and reagents (LISS and 
PEG from ImmucorGamma). Maternal serum was 
tested against commercially available ficin-modified 
RBCs in which serum and RBCs were incubated at 
37°C for 15 minutes followed by testing with anti-
human globulin (AHG). Adsorption of anti-Ku was 
carried out by incubation of maternal serum with 
KEL1+ and KEL1– RBCs at 37°C for 30 minutes and 
the absorbed serum was subsequently tested by the 
tube method. Titration of anti-Ku was performed by 
incubating serial saline dilutions of the serum with 
saline-suspended RBCs at 37°C for 60 minutes fol-
lowed by testing with anti-human globulin. Titer 
was assigned to the highest dilution which resulted 
in macroscopic reactions. Eluate from cord RBCs 
was prepared by using commercially available kit 
(Elu-Kit II, ImmucorGamma) according to manu-
facturer’s instructions. DTT treatment of RBCs was 
accomplished by adding one volume of a 50% RBC 
suspension to an equal volume of 0.01M DTT solu-
tion; the mixture was then incubated at 37°C for 15 
minutes. The excess DTT was removed by washing 
the treated RBCs 4 times with saline.
Case Report and Results
 A 35-year-old previously nontransfused woman 
from Ecuador, gravida 3, para 3 (G3P3), was first re-
ferred to our reference laboratory in February 2006. 
At this time she had delivered her third baby at a 
local hospital. On routine workup on a sample from the la-
bor and delivery floor, she was found to be group O, D+, 
and on antibody screening, she was found to have an anti-
body that reacted with RBCs in the AHG phase. The baby’s 
blood typed as group A, D+. Maternal sample testing was 
completed at our laboratory, and the findings are shown in 
Table 1. The titer of the maternal antibody was not deter-
mined.
 The serologic findings in 2006 described previously 
and in Table 1 demonstrated that the mother was K0 and 
had anti-Ku in her serum. The baby was group A, D+ and 
required phototherapy after birth, most likely owing to 
maternal anti-A. However, the details about the baby were 
not available. The mother indicated that this baby did not 
require any transfusions during pregnancy or after delivery. 
The mother also reported that the first two babies were 
born in Ecuador and neither of them had required any pho-
totherapy or transfusions.
 This patient presented again in January 2010 at ap-
proximately 35 weeks of gestation with her fourth preg-
nancy (G4P3). A prenatal blood sample obtained at this 
time was sent to our laboratory for workup. The maternal 
sample typed as group O, D+. Serologic findings are shown 
in Table 2.





Nonenhanced panel Negative at IS and 37°C
Positive reactions (2+ to 4+) 
with all panel RBCs at AHG
Pan-reactive antibody
LISS panel Positive at IS, 1+ at 37°C, 
and 3+ to 4+ at AHG with all 
panel RBCs
Pan-reactive antibody with 
stronger reactions at AHG
Ficin enzyme panel 1+ at 37°C and 3+ at AHG 
with all RBCs




No reactions at AHG with all 
six panel RBCs
Findings suggest antibody 
specificity may reside in Kell 
group system
Maternal serum ad-
sorbed with KEL1+ 
RBCs tested in a 
LISS panel
No reactions at IS, 37°C, and 
AHG
Adsorption with KEL1+ 
RBCs removed the antibody
Maternal serum 
tested against K0 
RBCs
Negative reaction Antibody does not react with  
K0 RBCs. Findings suggest 
presence of anti-Ku
Maternal RBC studies




Low- and high- 
prevalence antigens absent; 
in-house antisera used for 
typing except for KEL1, 
KEL2, and KEL3





AHG = anti-human globulin; IS = immediate spin.
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Absense of hemolytic disease
 A fetal ultrasound performed at 36 weeks and 1 day’s 
gestation demonstrated the peak systolic velocity of 0.52 
m/s on the middle cerebral artery Doppler, which is nor-
mal. A follow-up ultrasound to rule out hydrops fetalis or 
fetal anemia was also performed 4 days later and showed 
normal peak systolic velocity of 0.44 m/s. In addition, there 
were no signs of hydrops fetalis.
 The mother donated a unit of whole blood at 37 weeks 
of gestation for her own use and also for her baby if needed 
after the birth. The mother went into spontaneous labor the 
day after the blood donation at 37 weeks of gestation and 
delivered a normal healthy boy. At birth, the baby’s Hb level 
was 22.7 g/dL, and the total bilirubin was 1.3 mg/dL. The 
baby’s Hb levels on day 1 were 20.7 and 21.1 g/dL. On days 
2 and 3, these values were 17.5 and 18.2 g/dL, respectively. 
The baby’s total bilirubin values are shown in Table 3. The 
highest total bilirubin, 15.4 mg/dL, was seen on day 3. It 
should be noted that for term newborns, the upper 95th 
percentile total bilirubin at 72 hours is 16.0 mg/dL.11 At this 
point, the baby was briefly treated with phototherapy and 
discharged home on day 5 in good condition.
 A cord blood sample was tested in our laboratory, and 
the baby was found to be group O, D+. Cord RBCs and se-
rum testing results are shown in Table 2.
Discussion 
 Anti-Ku is seen in individuals who are K0. Anti-Ku re-
acts with all RBCs except those that are K0. K0 RBCs do not 
react with the antisera directed against other Kell system 
antigens, such as KEL1, KEL2, KEL3, KEL4, etc. In our 
case, maternal RBCs were tested for the presence of several 
Kell antigens, namely KEL1, KEL2, KEL3, KEL4, KEL6, 
KEL7, KEL11, KEL13, and KEL18, and all were found to 
be lacking. Maternal serum in our case also showed reac-
tions with all panel RBCs tested with LISS enhancement, 
and these reactions were abolished when tested against a 
DTT-treated panel. The maternal serum also did not react 
against cells from a K0 individual. These findings support 
the conclusion that the woman in our case was K0 and had 
developed anti-Ku. A Ku-like antibody has been described in 
individuals whose RBCs are classified as Kmod.  RBCs with the 
Kmod phenotype give weak reactions with antisera directed 
against Kell antigens.12 In our case, maternal RBCs failed to 
give any reactions with such antisera, supporting the conclu-
sion that the woman in our case was K0 and not Kmod.






  LISS panel Positive to 1+ at IS, + 
to 1+ at 37°C, and 4+ 
at AHG with all panel 
RBCs
A panreactive antibody 
with stronger reactions 
at AHG
DTT-treated, ficin-
treated, and PEG 
panels
Negative reactions 
with all panel RBCs
Antibody not reactive 
with DTT-treated 
RBCs suggests Kell 
group related antibody. 
Kell antigens are 
generally considered 
resistant to ficin. So, 





Titer against KEL1+ 
RBCs 








tested against K0  
RBCs
Negative reaction Antibody does not 







Rh phenotype C+,c+,E+,e+ R1R2 phenotype
DAT 4+ IgG Positive DAT
DAT on  
chloroquine-treated 
RBCs
Positive Unable to remove 
bound antibody to 
perform phenotyping 
of Kell group antigens
Cord serum testing
   Serum screening 
   with LISS and gel
Negative reactions Absence of antibody in 
the serum
Eluate from cord RBC testing
Eluate tested with 
nonenhanced panel 
RBCs
3+ at AHG with all 
panel RBCs
Panreactive antibody
Eluate tested with 
DTT-treated panel 
RBCs
No reactions Abolition of anti-
body reactivity with 
DTT-treated RBCs 
suggests Kell group 
specificity
AHG = anti-human globulin; IS = immediate spin.
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 We are aware of four published cases of anti-Ku–
mediated AFN.5–8. One of these reports is published in a 
non-English journal, and we were unable to obtain the de-
tails of the case.5 The other three cases show severe AFN. 
For instance, a case of AFN has been described in which 
the newborn developed anemia with a Hb of 10.7 g/dL 10 
hours after birth and the baby’s bilirubin was 18.1 mg/dL.6 
The baby was given three exchange transfusions of KEL: 
–1 blood. Further studies showed that the mother had the 
phenotype K0 and the baby’s phenotype was KEL: –1,2, 
–3,–4,–6, 7. The mother had high-titer anti-Ku. In two other 
cases, intrauterine transfusions of RBCs were needed.7,8 In 
one of the two cases, the fetus required regular intrauterine 
transfusion to manage severe anemia with a Hb of 3 g/dL.7 
In this case, the mother was also treated with recombinant 
erythropoietin. A baby boy was delivered at 36 weeks of ges-
tation with a Hb of 15.8 g/dL. After birth, the baby devel-
oped only mild hyperbilirubinemia. On the 15th day of life, 
the infant’s Hct was 27.3%; both his reticulocyte count and 
erythropoietin level were low. The infant was subsequently 
treated with recombinant erythropoietin. In the second 
case that required intrauterine RBC transfusions, a preg-
nant 30-year-old woman was first seen at 18 weeks of ges-
tation and was found to have anti-Ku following one trans-
fusion, one pregnancy, and two abortions.8 She was of the 
K0 phenotype. The titer of the antibody ranged from 1024 
to 4096 during the pregnancy. At the 26th week of gesta-
tion, the fetus was found to have hydrops fetalis and un-
derwent emergency intrauterine transfusion with maternal 
RBCs. By 35 weeks of gestation, while receiving recombi-
nant erythropoietin, the mother donated four units of RBCs 
for four additional fetal intrauterine exchange transfusions. 
The baby was delivered by cesarean section, required pho-
totherapy but did not need exchange transfusion.
 As described previously, in our case, there was no clini-
cal evidence for AFN even though the mother had IgG anti-
Ku and the newborn cord RBCs had a positive DAT with 
anti-IgG and an eluate that reacted with all RBCs tested but 
not with DTT-treated RBCs. Maternal antibody titer in our 
case was 256 and is less than in the previously reported case 
described earlier. As our case illustrates, anti-Ku titer in it-
self may not be predictive of AFN (which is typical of Kell 
antibodies). The fetus in our case had a carotid artery Dop-
pler study that showed absence of anemia. At birth, cord 
blood hemoglobin and bilirubin values were normal. A mild 
elevation in total bilirubin was seen on the third day of life, 
which was treated with phototherapy, and the newborn was 
discharged in good condition on day 5. The lack of AFN in 
our case could be attributable to an anti-Ku IgG subclass. 
For instance, IgG2 and IgG3 subclass antibodies are not 
transported across the placenta as readily as IgG1 and IgG4. 
Our laboratory is not able to perform subclass determina-
tion of IgG antibody, and therefore such studies were not 
performed. A monocyte monolayer assay to assess the clinical 
significance of maternal anti-Ku would have been helpful, 
but these latter studies were not performed.
 The lack of AFN with anti-Ku has been observed pre-
viously (personal communication from Marion Reid). Our 
case contributes valuable information on serologic and 
clinical findings about the lack of AFN from anti-Ku in view 
of the fact that K0 individuals are rare, the opportunities to 
study AFN from anti-Ku are rare, and the publication bias is 
generally toward reporting those cases in which infants are 
affected.
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